Navigation Links
PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
Date:7/31/2009

g price of the common stock on the NYSE Amex on July 24, 2009 plus $0.041667. Principal and interest are due at maturity two years from the closing of the private placement.

In connection with the transaction, the Company also issued Warrants to purchase up to 2.6 million shares of PharmAthene common stock at $2.50 per share, the closing price of PharmAthene's common stock on the NYSE Amex on July 24, 2009. The Warrants will be exercisable for a period of five years beginning six months after the closing of the private placement. The Company did not engage a placement agent in connection with this transaction.

About the Securities

The securities that are being sold in the transaction have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. PharmAthene has agreed to file a registration statement under the Securities Act to register the shares of common stock issuable upon conversion of the notes and upon any exercise of the warrants for public resale from time to time in the future. There can be no assurances that the registration statement will be declared effective. The information contained in this press release does not constitute an offer for the sale of any securities.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for th
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
5. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
6. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. BioVex Closes Second Round of Series E Financing
9. Pharmaxis Closes Share Purchase Plan
10. The closest look ever at native human tissue
11. Helix BioPharma closes $16.9 million private placement of common shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Hospitals in Western Pennsylvania Earn Designation, PITTSBURGH, ... named Allegheny General Hospital, UPMC Presbyterian Shadyside and ... Rare Cancers., Complex and rare cancers comprise ... making it difficult for patients to locate or,research ...
... has announced,development of a chemically synthesized vaccine specific ... patented Replikins(TM) technology.,When the vaccine was administered orally ... Taura virus. The specificity of the protective,effect was ... active,regions in the vaccine, and as a result ...
... Prescribing of Copaxone over an Interferon-Beta Therapy, According to a ... ... Resources, WALTHAM, Mass., March 11 Decision Resources, one ... issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient share among ...
Cached Biology Technology:Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... may help to identify which depressed patients will ... signal, detectable by noninvasive imaging, also holds clues ... for drug development, say National Institutes of Health ... of several such markers, including factors detectable in ...
... pollution and heavy fishingare adding insult to injury in ... by the Wildlife Conservation Society and the University of ... found that pollution and overfishing on reef systems have ... wormsthat further degrade corals, a discovery that underlines the ...
... University of Oklahoma research team has been awarded a five-year, ... that can lead to a greater understanding of human diseases ... infections. The goal of the NIH grant is to ... research in Oklahoma. "This is the first NIH ...
Cached Biology News:Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6Microbes, sponges, and worms add to coral reef woes 2Microbes, sponges, and worms add to coral reef woes 3OU research group awarded $9.7 million NIH CoBRE grant in structural biology 2
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... Polystyrene covers can be ... Ridged covers for stacking ... Non-ridged covers for use with ... covers, ridged and non-ridged, are ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
... made from an inert polymer with a unique ... 384 split septum caps for use with 384-well ... PCR when used in conjunction with screw or ... standard pipetting equipment 384 septum caps may ...
Biology Products: